{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:13:33Z","timestamp":1788779613117,"version":"build-2803163510"},"reference-count":23,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      This study aimed to evaluate differences among three patient groups with suspected recurrent esophageal carcinoma, defined by\n                      <jats:sup>18<\/jats:sup>\n                      F-fluorodeoxyglucose positron emission tomography\/computed tomography (\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT) findings, in quantitative and semiquantitative PET\/CT parameters and serum tumor markers, and to assess their impact on progression-free survival (PFS) and overall survival (OS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study included 77 patients with positive\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT findings between January 2014 and December 2025. Based on\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT findings, patients were classified into three groups: G1 (isolated locoregional recurrence), G2 (isolated metastases), and G3 (both locoregional disease and metastases). Semiquantitative and quantitative\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT parameters, histopathological characteristics, and blood tumor marker levels were compared among the groups. For survival analysis, patients were stratified into low and high groups according to the median value of each parameter.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Elevated carcinoembryonic antigen (CEA) levels were significantly more frequent in G2 and G3 compared with G1 (p = 0.005), while no significant difference was observed for carbohydrate antigen 19-9 (CA19-9) levels (p = 0.280). Significant differences in all analyzed\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT parameters were found among the three groups, with the highest values in G3. Patients with lower maximal standardized uptake values (SUVmax) and SUVmean values demonstrated significantly longer PFS and OS. Lower metabolic tumor volume (MTV) and total lesion glycolysis (TLG) values were associated with significantly longer progression-free survival (PFS), while overall survival (OS) was also longer, although without statistical significance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Studies stratifying patients by isolated locoregional recurrence, isolated metastases, and combined locoregional\/metastases on\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT remain limited. Our findings suggest that disease spread patterns and semiquantitative\/quantitative\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT parameters may provide important prognostic value in patients with esophageal carcinoma.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2026-0047","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:00:23Z","timestamp":1788778823000},"page":"346-355","source":"Crossref","is-referenced-by-count":0,"title":["<sup>18<\/sup>\n                    F-FDG PET\/CT-based recurrence patterns and survival outcomes in esophageal carcinoma: a single center experience"],"prefix":"10.2478","volume":"60","author":[{"given":"Milica","family":"Kotur","sequence":"first","affiliation":[{"name":"1 Center for Nuclear Medicine with PET, University Clinical Center of Serbia , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Strahinja","family":"Odalovic","sequence":"additional","affiliation":[{"name":"1 Center for Nuclear Medicine with PET, University Clinical Center of Serbia , Belgrade , Serbia"},{"name":"2 Faculty of Medicine, University of Belgrade , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Petrovic","sequence":"additional","affiliation":[{"name":"1 Center for Nuclear Medicine with PET, University Clinical Center of Serbia , Belgrade , Serbia"},{"name":"2 Faculty of Medicine, University of Belgrade , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Pantic","sequence":"additional","affiliation":[{"name":"1 Center for Nuclear Medicine with PET, University Clinical Center of Serbia , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidora Grozdic","family":"Milojevic","sequence":"additional","affiliation":[{"name":"1 Center for Nuclear Medicine with PET, University Clinical Center of Serbia , Belgrade , Serbia"},{"name":"2 Faculty of Medicine, University of Belgrade , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana Sobic","family":"Saranovic","sequence":"additional","affiliation":[{"name":"1 Center for Nuclear Medicine with PET, University Clinical Center of Serbia , Belgrade , Serbia"},{"name":"2 Faculty of Medicine, University of Belgrade , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Predrag","family":"Sabljak","sequence":"additional","affiliation":[{"name":"2 Faculty of Medicine, University of Belgrade , Belgrade , Serbia"},{"name":"3 Clinic for Digestive Surgery, University Clinical Center of Serbia , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Artiko","sequence":"additional","affiliation":[{"name":"1 Center for Nuclear Medicine with PET, University Clinical Center of Serbia , Belgrade , Serbia"},{"name":"2 Faculty of Medicine, University of Belgrade , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"2026090711001905460_j_raon-2026-0047_ref_001","doi-asserted-by":"crossref","unstructured":"Jiang W, Zhang B, Xu J, Xue L, Wang L. Current status and perspectives of esophageal cancer: a comprehensive review. Cancer Commun 2025; 45: 281-331. doi: 10.1002\/cac2.12645","DOI":"10.1002\/cac2.12645"},{"key":"2026090711001905460_j_raon-2026-0047_ref_002","doi-asserted-by":"crossref","unstructured":"Lander S, Lander E, Gibson MK. Esophageal cancer: overview, risk factors, and reasons for the rise. Curr Gastroenterol Rep 2023; 25: 275-9, doi: 10.1007\/s11894-023-00899-0","DOI":"10.1007\/s11894-023-00899-0"},{"key":"2026090711001905460_j_raon-2026-0047_ref_003","doi-asserted-by":"crossref","unstructured":"Sung J, Lin D, Fitzgerald R, Sharma P, Law S, Ilson D. Carcinoma of esophagus. J Gastroenterol Hepatol 2025; 40: 1861-75. doi:10.1111\/jgh.16990","DOI":"10.1111\/jgh.16990"},{"key":"2026090711001905460_j_raon-2026-0047_ref_004","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers [Internet]. [cited 2026 Mar 5]. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1433"},{"key":"2026090711001905460_j_raon-2026-0047_ref_005","unstructured":"National Cancer Institute. Esophageal Cancer Treatment (PDQ\u00ae)\u2013Patient Version [Internet]. Bethesda (MD): National Cancer Institute; [cited 2026 Mar 15]. Available at: https:\/\/www.cancer.gov\/types\/esophageal\/patient\/esophageal-treatment-pdq."},{"key":"2026090711001905460_j_raon-2026-0047_ref_006","doi-asserted-by":"crossref","unstructured":"Samoylova ML, Rajaram R. The evolving role of systemic therapy in locoregionally advanced esophageal cancer: a narrative review. Ann Esophagus 2025; 8: 20. doi: 10.21037\/aoe-25-11","DOI":"10.21037\/aoe-25-11"},{"key":"2026090711001905460_j_raon-2026-0047_ref_007","doi-asserted-by":"crossref","unstructured":"Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003; 97: 1616-23. doi: 10.1002\/cncr.11228","DOI":"10.1002\/cncr.11228"},{"key":"2026090711001905460_j_raon-2026-0047_ref_008","doi-asserted-by":"crossref","unstructured":"Kim N, Cho H, Yun M, Park KR, Lee CG. Prognostic values of mid-radiotherapy 18F-FDG PET\/CT in patients with esophageal cancer. Radiat Oncol 2019; 14: 27. doi: 10.1186\/s13014-019-1232-1","DOI":"10.1186\/s13014-019-1232-1"},{"key":"2026090711001905460_j_raon-2026-0047_ref_009","doi-asserted-by":"crossref","unstructured":"Karahan \u015een NP, Aksu A, \u00c7apa Kaya G. Volumetric evaluation of staging 18F-FDG PET\/CT images in patients with esophageal cancer. Mol Imaging Radionucl Ther 2022; 31: 216-22. doi: 10.4274\/mirt.galenos.2022.38980","DOI":"10.4274\/mirt.galenos.2022.38980"},{"key":"2026090711001905460_j_raon-2026-0047_ref_010","doi-asserted-by":"crossref","unstructured":"Goense L, van Rossum PS, Reitsma JB, Lam MG, Meijer GJ, van Vulpen M. Diagnostic performance of 18F-FDG PET and PET\/CT for the detection of recurrent esophageal cancer after treatment with curative intent: a systematic review and meta-analysis. J Nucl Med 2015; 56: 995-1002. doi: 10.2967\/jnumed.115.155580","DOI":"10.2967\/jnumed.115.155580"},{"key":"2026090711001905460_j_raon-2026-0047_ref_011","doi-asserted-by":"crossref","unstructured":"Clark GW, Ireland AP, Hagen JA, Collard JM, Peters JH, De Meester TR. Carcinoembryonic antigen measurements in the management of esophageal cancer: an indicator of subclinical recurrence. Am J Surg 1995; 170: 597-601. doi: 10.1016\/s0002-9610(99)80023-3","DOI":"10.1016\/S0002-9610(99)80023-3"},{"key":"2026090711001905460_j_raon-2026-0047_ref_012","unstructured":"Mao YS, Zhang DC, Zhao XH, Wang LJ, Qi J, Li XX. [Significance of CEA, SCC and Cyfra21-1 serum test in esophageal cancer]. [Chinese]. Zhonghua Zhong Liu Za Zhi 2003; 25: 457-60. doi: 10.3760\/cma.j.issn.0253-3766.2003.05.112"},{"key":"2026090711001905460_j_raon-2026-0047_ref_013","doi-asserted-by":"crossref","unstructured":"Das S, Kakoti LM, Ahmed S, Sarma A, Kataki AC. Study of serum CEA and CA 19-9 in esophageal squamous carcinoma and ROC curve analysis. Asian Pac J Cancer Biol 2020; 5: 141-5. doi: 10.31557\/APJCB.2020.5.4.141","DOI":"10.31557\/apjcb.2020.5.4.141-145"},{"key":"2026090711001905460_j_raon-2026-0047_ref_014","doi-asserted-by":"crossref","unstructured":"Ansari F, Rai A, Shukla S. Study of carcinoma embryonic antigen and carbohydrate antigen 19-9 levels in patients of esophageal cancer. Int Surg J 2021; 8: 3274-8. doi: 10.18203\/2349-2902.isj20214060","DOI":"10.18203\/2349-2902.isj20214060"},{"key":"2026090711001905460_j_raon-2026-0047_ref_015","doi-asserted-by":"crossref","unstructured":"Ter Veer E, van Kleef JJ, Schokker S, van der Woude SO, Laarman M, Haj Mohammad N, et al. Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: a systematic review and meta-analysis. Eur J Cancer 2018; 103: 214-26. doi: 10.1016\/j.ejca.2018.07.132","DOI":"10.1016\/j.ejca.2018.07.132"},{"key":"2026090711001905460_j_raon-2026-0047_ref_016","doi-asserted-by":"crossref","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kaspe S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet 2019; 393: 1948-57, doi: 10.1016\/S0140-6736(18)32557-1","DOI":"10.1016\/S0140-6736(18)32557-1"},{"key":"2026090711001905460_j_raon-2026-0047_ref_017","doi-asserted-by":"crossref","unstructured":"Mantziari S, Pomoni A, Prior JO, Winiker M, Allemann P, Demartines N, et al. 18F-FDG PET\/CT-derived parameters predict clinical stage and prognosis of esophageal cancer. BMC Med Imaging 2020; 20: 7. doi: 10.1186\/s12880-019-0401-x","DOI":"10.1186\/s12880-019-0401-x"},{"key":"2026090711001905460_j_raon-2026-0047_ref_018","doi-asserted-by":"crossref","unstructured":"Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR 2010; 31: 496-505. doi: 10.1053\/j.sult.2010.10.001","DOI":"10.1053\/j.sult.2010.10.001"},{"key":"2026090711001905460_j_raon-2026-0047_ref_019","doi-asserted-by":"crossref","unstructured":"Kommi S, Rallapeta RP, Subramanian BV, Yadagiri LA, Hulikal N, Chandramaliteeswaran C, et al. Utility of [18F]FDG-PET\/CT in initial staging and management of patients with esophageal carcinoma: a tertiary care center experience. Indian J Nucl Med 2024; 39: 329-34. doi: 10.4103\/ijnm.ijnm_118_23","DOI":"10.4103\/ijnm.ijnm_118_23"},{"key":"2026090711001905460_j_raon-2026-0047_ref_020","doi-asserted-by":"crossref","unstructured":"Al-Taan OS, Eltweri A, Sharpe D, Rodgers PM, Ubhi SS, Bowrey DJ. Prognostic value of baseline FDG uptake on PET-CT in esophageal carcinoma. World J Gastrointest Oncol 2014; 6: 139-44. doi: 10.4251\/wjgo.v6.i5.139","DOI":"10.4251\/wjgo.v6.i5.139"},{"key":"2026090711001905460_j_raon-2026-0047_ref_021","doi-asserted-by":"crossref","unstructured":"Korkmaz U, Hacioglu MB, Kostek O, Sut N, Kodaz H, Erdogan B, et al. The relationship between FDG PET\/CT-defined metabolic parameters and the histopathological subtype of oesophageal carcinomas. Pol J Radiol 2020; 85: e254-e60. doi: 10.5114\/pjr.2020.95945","DOI":"10.5114\/pjr.2020.95945"},{"key":"2026090711001905460_j_raon-2026-0047_ref_022","doi-asserted-by":"crossref","unstructured":"Hatt M, Visvikis D, Albarghach NM, Tixier F, Pradier O, Cheze-le Rest C. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging 2011; 38: 1191-202. doi: 10.1007\/s00259-011-1755-7","DOI":"10.1007\/s00259-011-1755-7"},{"key":"2026090711001905460_j_raon-2026-0047_ref_023","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez A, Infante JR, Quir\u00f3s J, Rayo JI, Serrano J, Moreno M, et al. Baseline 18F-FDG PET\/CT quantitative parameters as prognostic factors in esophageal squamous cell cancer. Rev Esp Med Nucl Imagen Mol 2022; 41: 164-70. doi: 10.1016\/j.remnie.2021.07.006","DOI":"10.1016\/j.remnie.2021.07.006"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2026-0047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:00:36Z","timestamp":1788778836000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2026-0047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9,7]]},"published-print":{"date-parts":[[2026,9,1]]}},"alternative-id":["10.2478\/raon-2026-0047"],"URL":"https:\/\/doi.org\/10.2478\/raon-2026-0047","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}